The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Johnson & Johnson/Janssen; Kura Oncology; Mitsubishi Tanabe Pharma; shivanka Research
Research Funding - Abbvie (Inst); Abdera Thereapeutics (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Syndax (Inst); Systimmune (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)
 
Russell Pachynski
Stock and Other Ownership Interests - Pixie Biosciences, Inc
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; Eisai; Exelixis; Janssen Oncology; Macrogenics; Pfizer/EMD Serono; Sanofi; Tolmar Therapeutics
Speakers' Bureau - Bayer; Merck
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions comprising chemerin and methods of use thereof; Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Shahneen Sandhu
Stock and Other Ownership Interests - Advancell
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Consulting or Advisory Role - Abbvie (Inst); Advancell (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Roche/Genentech (Inst); Skyline Diagnostics (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Aaron Hansen
Consulting or Advisory Role - Bayer; Full-Life technology; Janssen; Merck
Speakers' Bureau - Astellas Scientific and Medical Affairs Inc; Janssen; MSD Oncology
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Full-Life Technologies (Inst); Fusion Pharmaceuticals (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Kevin Zarrabi
Honoraria - Aptitude Health; Association of Community Cancer Centers (ACCC); Curio Science; OncLive Clinical Congress Consultants
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai; Exelixis; Johnson & Johnson/Janssen; Pfizer; Survivornet
Research Funding - 858 Therapeutics (Inst); Amgen (Inst); DualityBio (Inst); Exelixis (Inst); IDEAYA Biosciences (Inst); Johnson & Johnson/Janssen (Inst); Vaccitech (Inst)
Travel, Accommodations, Expenses - Janux Therapeutics; Telix Pharmaceuticals
 
Craig Gedye
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Icon Cancer Care; Merck Sharp & Dohme (Inst); Novotech; SERVIER (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Nehal Lakhani
Consulting or Advisory Role - Janssen Oncology
Research Funding - Adcentrx (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Biosplice (Inst); Bright Peak Therapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Celgene (Inst); Circle Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Day One Biopharmaceuticals (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Treeline Biosciences (Inst); Treeline Biosciences (Inst); Treeline Biosciences (Inst)
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ipsen; Merck Serono
 
Justin Lebenthal
Consulting or Advisory Role - Third Bridge; Topline Bio
 
Mary O'Keeffe
No Relationships to Disclose
 
Samantha Hopkins
No Relationships to Disclose
 
Nancy Huang
No Relationships to Disclose
 
Debopriya Ghosh
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Ligi Mathews
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Regina Brown
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Vincent Lin
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Josh Lauring
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Abbvie (I); Galderma (I)
Speakers' Bureau - Abbvie (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Celgene (I); Dermavant (I); Galderma (I); Lilly (I)
Travel, Accommodations, Expenses - Abbvie (I); Boehringer Ingelheim (I); Dermavant (I); Galderma (I); Lilly (I)
 
Sherry Wang
Employment - J&J Innovative Medicines
Stock and Other Ownership Interests - Johnson & Johnson/Janssen; NGM Biopharmaceuticals
Patents, Royalties, Other Intellectual Property - patent for pasritamig dosing schedule
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Victor Villalobos
Employment - Janssen Oncology
Stock and Other Ownership Interests - Janssen Oncology
 
David Wise
Stock and Other Ownership Interests - Doximity
Honoraria - OncLive; ScientiaCME
Consulting or Advisory Role - Bayer; Janssen; K36; OncoC4; Pfizer
Travel, Accommodations, Expenses - Bayer; Bayer; Pfizer